RecruitingNeisseria Meningitidis
MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults
Eligible age
18–25 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to determine the immunogenicity of certain vaccines in protecting against meningitis B (MenB) in young adults who have previously received a different MenB vaccine. The main questions it aims to answer are: * How many participants are protected against four key types of MenB bacteria before and after getting the new vaccine? * How strong is the immune response after vaccination, and how many people show a noticeable boost in immune response?
Sponsor: Emory University
You may qualify if…
- ✓ Provides written informed consent before any study procedures are performed.
- ✓ Be able to understand and agree to comply with planned study procedures and be available for all study visits.
- ✓ Subject is in good health as determined by vital signs, medical history, targeted physical examination (if indicated), and the judgment of the investigator.
- ✓ Vaccinated with 2-dose Bexsero primary series at least 2.5 years before vaccination. Must confirm vaccination status and dates of administration through GRITS, healthcare provider, or other official documentation
- ✓ Women of childbearing potential must agree to use or have practiced true abstinence2 or use at least one acceptable primary form of contraception from 28 days prior through 28 days after vaccination.
- ✓ Women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours before vaccination
You may not qualify if…
- ✕ Subject has an acute illness with fever (temperature ≥100.4 °F) within 72 hours before vaccine administration.
- ✕ Subject is currently pregnant or breastfeeding an infant/child.
- ✕ Has any medical disease or condition that, in the opinion of the site PI or appropriate sub-investigator, precludes study participation. (Including acute, subacute, intermittent,t or chronic medical disease or condition that would place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the subject's successful completion of this trial. Chronic medical conditions that are stable, with no escalation in medication doses or new medications administered in the preceding 3 months, will not be considered exclusionary.)
- ✕ Presence of self-reported or medically documented significant medical or psychiatric condition(s) as determined by the investigator.
- ✕ Received or plans to receive a licensed, live vaccine within 4 weeks before or after the study vaccination.
- ✕ Received or plans to receive a licensed, inactivated vaccine within 2 weeks before through 4 weeks after the study vaccination.
- ✕ Any previous severe hypersensitivity or anaphylactic reaction to any vaccine or vaccine-related component
- ✕ Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Where it's recruiting
Georgia
Atlanta
Source: ClinicalTrials.gov · NCT07197762 · last updated 2025-12-22